G49108TO
| Organisms | Evidence |
|---|---|
| Streptococcus pneumoniae | |
| Mus musculus (house mouse) | |
| Saccharomyces cerevisiae (brewer's yeast) | |
| Sus scrofa (pig) | |
| Rattus norvegicus (Norway rat) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT1 | UDP-Gal |
|
R |
|
R | |
| B4GALT2 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
| B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
| B3GALT5 | UDP-Gal |
|
R |
|
R |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-thio-p-Nitrophenyl |
|
[beta]-1-thio-p-Nitrophenyl | |
| B4GALT3 | UDP-Gal |
|
4-Me-lumbelyl-[beta] |
|
4-Me-lumbelyl-[beta] | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-4-methyl-umbelliferyl |
|
[beta]-1-4-methyl-umbelliferyl | |
| B4GALT1 | UDP-Gal |
|
|
| Pathway Name | Organism |
|---|---|
| Antimicrobial peptides | Sus scrofa |
| Antimicrobial peptides | Rattus norvegicus |
| Antimicrobial peptides | Dictyostelium discoideum |
| Antimicrobial peptides | Bos taurus |
| Antimicrobial peptides | Canis familiaris |
| Antimicrobial peptides | Mus musculus |
| Antimicrobial peptides | Gallus gallus |
| Antimicrobial peptides | Homo sapiens |
| Antimicrobial peptides | Drosophila melanogaster |
| Antimicrobial peptides | Xenopus tropicalis |
RES 1b:b-dglc-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 35420322 | Molecular docking unveils the potential of andrographolide derivatives against COVID-19: an in silico approach | Veerasamy R | 2022 Apr 14 |
|
| 35325595 | Facile discovery of surrogate cytokine agonists | Yen M | 2022 Apr 14 |
|
| 35247328 | Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases | Chang A | 2022 Apr 14 |
|
| 35344711 | Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody | Li C | 2022 Apr 14 |
|
| 35422493 | O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGgamma interaction | He X | 2022 Apr 14 |
|
| 35419655 | Simulations suggest double sodium binding induces unexpected conformational changes in thrombin | Wu D | 2022 Apr 13 |
|
| 35385697 | Epithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response dependent on tuft cell hyperplasia and Gasdermin C | Zhao M | 2022 Apr 12 |
|
| 35414690 | The intra-mitochondrial O-GlcNAcylation system rapidly modulates OXPHOS function and ROS release in the heart | Dontaine J | 2022 Apr 12 |
|
| 35479087 | Inhibition of O-GlcNAcylation Decreases the Cytotoxic Function of Natural Killer Cells | Feinberg D | 2022 Apr 11 |
|
| 35394827 | Cryo-EM structures of the human surfactant lipid transporter ABCA3 | Xie T | 2022 Apr 08 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025